Early outcomes with utilization of tissue plasminogen activator in COVID-19-associated respiratory distress: A series of five cases
Early outcomes with utilization of tissue plasminogen activator in COVID-19-associated respiratory distress: A series of five cases
复制标题
DOI：
10.1097/ta.0000000000002787
复制
发表时间：
2020-09-01
影响因子：
3.4
通讯作者：
Ashley, Dennis W.
中科院分区：
文献类型：
--
作者：
Christie, D. Benjamin, III;Nemec, Hannah M.;Ashley, Dennis W.
背景冠状病毒患者表现出不同程度的呼吸功能不全；许多人会发展为呼吸衰竭，出现传统支持策略难以治愈的严重急性呼吸窘迫综合征。提供者必须考虑替代疗法，以阻止或防止失代偿连锁反应导致暴发性呼吸衰竭。方法 这是一个由 5 名 COVID-19 阳性患者组成的病例系列，这些患者表现出严重的低氧血症、呼吸功能下降和氧气需求增加。患者符合以下标准：COVID-19 阳性、呼吸性能恶化、严重低氧血症 (Pao(2)
BACKGROUND Coronavirus patients demonstrate varying degrees of respiratory insufficiency; many will progress to respiratory failure with a severe version of acute respiratory distress syndrome refractory to traditional supportive strategies. Providers must consider alternative therapies to deter or prevent the cascade of decompensation to fulminant respiratory failure. METHODS This is a case-series of five COVID-19 positive patients who demonstrated severe hypoxemia, declining respiratory performance, and escalating oxygen requirements. Patients met the following criteria: COVID-19 positivity, worsening respiratory performance, severe hypoxemia (Pao(2)